IP Library › Granted Patent US 8,383,805
Granted Patent B2
US 8,383,805 · App. 13/080,334 · Granted Feb 26, 2013

RNAi modulation of SCAP and therapeutic uses thereof

Inventors: Juergen Soutschek (Sulgen, CH); Pamela Tan (Kulmbach, DE); Jay D. Horton (Plano, TX); Michael S. Brown (Dallas, TX); Joseph L. Goldstein (Dallas, TX); Young-Ah Moon (Irving, TX)
Assignees: Alnylam Pharmaceuticals, Inc.; Board of Regents, The University of Texas System
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,383,805
App. No.
13/080,334
Granted
Feb 26, 2013
Kind
B2
Abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.

Claims (9)

1. A double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene in a cell, wherein said dsRNA comprises a sense strand comprising SEQ ID NO:46 and an antisense strand comprising SEQ ID NO:45, and wherein said dsRNA is less than 30 nucleotides in length.

2. The dsRNA of claim 1 , wherein said dsRNA comprises at least one modified nucleotide.

3. The dsRNA of claim 2 , wherein said modified nucleotide is chosen from the group of: a 2′-O-methyl modified nucleotide, a nucleotide comprising a 5′-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group.

4. The dsRNA of claim 2 , wherein said modified nucleotide is chosen from the group of: a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide.

5. A cell comprising the dsRNA of claim 1 .

6. A pharmaceutical composition for inhibiting the expression of a SCAP gene in an organism, comprising a dsRNA and a pharmaceutically acceptable carrier, wherein the dsRNA comprises a sense strand comprising SEQ ID NO: 46 and an antisense strand comprising SEQ ID NO: 45, and wherein said dsRNA is less than 30 nucleotides in length.

7. A method for inhibiting the expression of a SCAP gene in a cell, the method comprising: (a) introducing into the cell a double-stranded ribonucleic acid (dsRNA), wherein the dsRNA comprises a sense strand comprising SEQ ID NO: 46 and an antisense strand comprising SEQ ID NO: 45, and wherein said dsRNA is less than 30 nucleotides in length; and (b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of a SCAP gene, thereby inhibiting expression of a SCAP gene in the cell.

8. A vector for inhibiting the expression of a SCAP gene in a cell, said vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes at least one strand of a dsRNA, wherein one of the strands of said dsRNA is SEQ ID NO: 45 or SEQ ID NO: 46, and wherein said dsRNA is less than 30 nucleotides in length.

9. A cell comprising the vector of claim 8 .

Continuity (4)
Continuation 12749159 · Mar 29, 2010
Division 11857120 · Sep 18, 2007
Provisional Application 60845289 · Sep 18, 2006
Related Publication 20110184047A1 · Jul 28, 2011